

Pilot study on the effects of oral immunonutrition on the quality of life in patients receiving palliative treatment for oesophageal and proximal gastric cancer.

Submission date 30/09/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 30/09/2005	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 05/03/2020	Condition category Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Mr Martin White

Contact details
North Cumbria Acute Hospitals NHS Trust
Cumberland Infirmary
Carlisle
United Kingdom
CA2 7HY

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
N0055143763

Study information

Scientific Title

Pilot study on the effects of oral immuno-nutrition on the quality of life in patients receiving palliative treatment for oesophageal and proximal gastric cancer.

Study objectives

Does EPA supplementation affect patients' quality of life and survival with known esophageal and proximal gastric cancer who are receiving non-curative treatments?

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Quality of life

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Cancer: Gastrointestinal

Interventions

Patients, after obtaining informed consent, are randomly assigned one of the nutritional supplements, both of similar calorific value but one contains EPA.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Measurements of QoL, weight etc. are made at monthly interval, follow-up until death.

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/06/2002

Completion date

30/06/2004

Eligibility

Key inclusion criteria

Patients with histologically diagnosed oesophageal or proximal gastric cancer that are not receiving curative treatment.

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

Not provided at time of registration

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/06/2002

Date of final enrolment

30/06/2004

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

North Cumbria Acute Hospitals NHS Trust

Carlisle

United Kingdom
CA2 7HY

Sponsor information

Organisation

Department of Health

Sponsor details

Richmond House
79 Whitehall
London
United Kingdom
SW1A 2NL
+44 (0)20 7307 2622
dhmail@doh.gsi.org.uk

Sponsor type

Government

Website

<http://www.dh.gov.uk/Home/fs/en>

Funder(s)

Funder type

Government

Funder Name

North Cumbria Acute Hospitals NHS Trust (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration